Bartlett & Co’s CONMED CNMD Stock Holding History

Bartlett & Co’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21	Closed	-$3K	–	489
2021 Q3	$3K	Buy	+21	New	+$2.75K	﹤0.01%	812

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Bartlett & Co's CNMD Position: Q4 2021 in Review

Bartlett & Co sold out of CONMED (CNMD) in Q4 2021, closing a stake of 21 shares — an estimated $3K sold.

Bartlett & Co first reported a position in CNMD in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 265 funds tracked by Wall St. Rank hold CNMD as of Q4 2021.

Bartlett & Co reported no remaining CONMED position as of Q4 2021 after selling out during the quarter.
Bartlett & Co sold 21 CONMED shares in Q4 2021, an estimated $3K.
Bartlett & Co first reported a position in CONMED in Q3 2021 and held it in 1 quarter.
Bartlett & Co's CONMED position peaked at $3K in Q3 2021.
265 funds tracked by Wall St. Rank held CONMED as of Q4 2021.

Based on Bartlett & Co's 13F filing for Q4 2021, filed 8 Mar 2022.